Summary:
COMBINE is a global program of clinical studies to investigate how well a new combination therapy taken once weekly, IcoSema (insulin icodec and semaglutide), controls blood sugar levels in people with diabetes. The investigational product once-weekly IcoSema will be compared with its individual components and with insulins taken daily. As part of the program, this study is comparing the effect and safety of once‑weekly IcoSema, with that of daily insulins, over a period of 14 months.
Qualified Participants Must:
• You may qualify for this study if you are an adult with type 2 diabetes who has been treated with a once or twice-daily insulin.
Qualified Participants May Receive:
This could be your chance to:
- Take a more active role in managing your diabetes
- Help others by contributing to medical research
You could be part of a clinical study program that helps regulatory authorities decide if a new combination therapy should be made available for people with type 2 diabetes.